Skip to content
PyrAmes
  • BP + Health
  • Our Pipeline
    • Our Pipeline
    • Boppli®
    • Bosimi®
    • Bosimi@Home™ Monitoring
  • Our Company
  • News & Updates
  • Contact Us

Month: January 2022

PyrAmes Technology Featured in Neonatal Intensive Care Journal

Posted on January 17, 2022 (August 26, 2022) by pyrames

The PyrAmes Boppli™ device is featured on page 11 in the Winter 2022 edition of Neonatal Intensive Care: The Journal of Perinatology-Neonatology. The article focuses on how the Boppli is being developed to meet the need for continuous, non-invasive blood pressure monitoring in the neonatal intensive care unit (NICU). […]

Read More…

Recent Posts

  • PyrAmes Wins Top Honor at the SCCM 2026 Discovery Critical Care Innovation Incubator for Innovation in Blood Pressure Monitoring
  • Industry Leading Journal Neonatology Features Boppli® Pivotal Clinical Study
  • PyrAmes recognized in American Heart Association’s Health Tech Competition
  • TEAMFund Global Health Innovator Award
  • PyrAmes Receives FDA Clearance for its Groundbreaking Boppli® Wearable Blood Pressure Monitoring Device

Recent Comments

    Archives

    • March 2026
    • May 2025
    • November 2023
    • October 2023
    • September 2023
    • August 2023
    • May 2023
    • April 2023
    • December 2022
    • October 2022
    • September 2022
    • February 2022
    • January 2022
    • December 2021
    • June 2021
    • April 2021
    • May 2020
    • April 2020
    • February 2020
    • December 2019
    • November 2019
    • October 2019
    • September 2019
    • June 2019

    Categories

    • news

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    PyrAmes is a digital health company focused on fundamentally transforming the delivery of health care through continuous blood pressure monitoring that is accurate, wireless and non-invasive. The comfort and ease of use of our platform has the potential to provide better blood pressure management for patients ranging from newborns to seniors. The FDA has granted Breakthrough Device Designation and 510(k) market clearance for our lead product Boppli®. The Bosimi® and Bosimi@Home™ platforms are currently under development and have not yet been cleared by the FDA for distribution.

    • Contact Us
    pyrmes-text
    • Privacy Policy
    • Financial Conflict of Interest Policy

    PYRAMES INC. REV CO-220

    Created by Howbridge © 2026 PyrAmes Inc. All rights reserved.